AbbVie vs Bristol Myers Squibb
ABBV and BMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABBV and BMY compare
AbbVie is the larger company, worth 4.1 times as much as Bristol Myers Squibb ($521B against $128B).
On earnings, Bristol Myers Squibb is cheaper: it trades at 13.9× trailing earnings, against 83.3× for AbbVie.
AbbVie grew revenue faster over the last twelve months (10.4% versus 4.2% for Bristol Myers Squibb).
Bristol Myers Squibb keeps more of each dollar of sales as profit, with a net margin of 18.5% compared with 9.8% at AbbVie.
Both pay dividends: AbbVie yields 2.3% and Bristol Myers Squibb 4.0%.
Bristol Myers Squibb scores higher on the StockData Score (14 against 10 for AbbVie), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABBV | BMY |
|---|---|---|
| Size and price | ||
| Market cap | $521B | $128B |
| Share price | $294.89 | $62.48 |
| Change, 1 year | 31.0% | 46.7% |
| Change, 5 years | 152% | 5.1% |
| Beta (5Y) | 0.29 | 0.25 |
| Employees | 57K | 33K |
| StockData Score | ||
| Total score | 10 | 14 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 2 |
| Dividend score | 3 | 5 (better) |
| Valuation | ||
| P/E | 83.3× | 13.9× (better) |
| P/S | 8.1× | 2.6× (better) |
| P/B | – | 5.5× |
| EV/EBITDA | 34.7× | 10.0× (better) |
| P/FCF | 28.6× | 13.7× (better) |
| PEG | – | 2.54 |
| FCF yield | 3.5% | 7.3% (better) |
| Fair value | $152.33 | $87.52 |
| Margin of safety | −93.6% | 28.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.4% (better) | 4.2% |
| Revenue growth, 5Y average | 6.0% (better) | 2.5% |
| Net income growth (TTM) | 67.7% (better) | 53.1% |
| EPS growth (TTM) | 68.6% (better) | 52.4% |
| EPS growth, 5Y average | −2.8% | – |
| Profitability | ||
| Gross margin | 71.5% (better) | 69.2% |
| Operating margin | 26.2% | – |
| Net margin | 9.8% | 18.5% (better) |
| FCF margin | 28.3% (better) | 18.6% |
| Return on equity | – | 44.1% |
| Return on invested capital | 20.1% | – |
| Financial health | ||
| Debt / equity | – | 1.83 |
| Net debt / EBITDA | 3.81 | 1.92 (better) |
| Interest coverage | 5.8× | – |
| Current ratio | 0.81 | 1.59 (better) |
| Altman Z-score | 2.86 (better) | 2.22 |
| Piotroski F-score | 8 | 8 |
| Dividends and buybacks | ||
| Dividend yield | 2.3% | 4.0% (better) |
| Payout ratio | 190% | 55.4% |
| Years of dividend growth | 11 | 16 (better) |
| Dividend growth, 5Y average | 6.6% (better) | 6.2% |
| Buyback yield | 0.29% | – |
| Shareholder yield | 2.6% | 4.0% (better) |
| Ownership | ||
| Held by institutions | 75.6% | 81.9% |
| Held by insiders | 0.09% | 0.05% |
| Insider net buying, 12 months | −$18.9M | −$2.3M (better) |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 0.92% | 2.2% |
Go deeper
- ABBV stock overview
- ABBV income statement
- ABBV valuation and score
- BMY stock overview
- BMY income statement
- BMY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.